Breyna Dosing for Asthma
For asthma treatment in patients 6 years and older, Breyna (budesonide 160 µg/formoterol 4.5 µg) is dosed as 2 inhalations twice daily, with the specific strength (80/4.5 or 160/4.5) determined by age and asthma severity. 1
Dosing by Age Group
Pediatric Patients (6 to <12 years)
- Dose: 2 inhalations of Breyna 80 mcg/4.5 mcg twice daily (morning and evening, approximately 12 hours apart) 1
- This is the only approved strength for this age group
- Maximum dose: 2 inhalations twice daily of the 80/4.5 strength
Adolescents and Adults (≥12 years)
Starting dose based on asthma severity:
- Initial therapy: 2 inhalations of Breyna 80 mcg/4.5 mcg twice daily 1
- Step-up option: If inadequate control after 1-2 weeks on the 80/4.5 strength, increase to 2 inhalations of Breyna 160 mcg/4.5 mcg twice daily 1
- Maximum dose: 2 inhalations of Breyna 160 mcg/4.5 mcg twice daily 1
Administration Details
Key administration points:
- Administer approximately 12 hours apart (morning and evening) 1
- Rinse mouth with water without swallowing after each use to reduce risk of oral candidiasis 1
- Prime before first use: shake well for 5 seconds, then release 2 test sprays into the air away from face 1
- Re-prime if not used for >7 days or if dropped 1
Critical Limitations
Do not exceed prescribed dosing: More frequent administration or higher number of inhalations than 2 inhalations twice daily is not recommended, as higher formoterol doses increase adverse effects 1
Not for acute relief: Breyna is NOT indicated for relief of acute bronchospasm. Patients should use a short-acting beta2-agonist (SABA) for immediate symptom relief between doses 1
No additional LABA: Patients using Breyna should not use additional long-acting beta2-agonists for any reason due to overdose risk 1
Dose Adjustment Strategy
If previously effective regimen fails:
- First verify proper inhaler technique and adherence
- For patients on 80/4.5: increase to 160/4.5 strength 1
- Consider adding additional inhaled corticosteroid
- Consider initiating oral corticosteroids if needed
- Re-evaluate the entire therapeutic regimen 1
Time to benefit: Improvement can occur within 15 minutes, but maximum benefit may require 2 weeks or longer 1
Comparison to Guidelines
The FDA-approved dosing aligns with the 2007 EPR-3 guidelines, which recommend budesonide/formoterol combination therapy twice daily for moderate to severe persistent asthma in patients ≥12 years 2. The 2020 NAEPP updates further support ICS-formoterol as both maintenance and reliever therapy in patients ≥4 years with moderate to severe persistent asthma 3, 4, though the specific "maintenance and reliever therapy" (MART) regimen differs from Breyna's fixed twice-daily dosing approved by the FDA.